Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location.


Journal

Medical molecular morphology
ISSN: 1860-1499
Titre abrégé: Med Mol Morphol
Pays: Japan
ID NLM: 101239023

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 04 06 2019
accepted: 13 08 2019
pubmed: 23 8 2019
medline: 6 11 2020
entrez: 22 8 2019
Statut: ppublish

Résumé

The biliary tract cancer (BTC) covers a range of carcinomas, including intrahepatic cholangiocarcinoma (ICC), cholangiolocellular carcinoma (CoCC), perihilar cholangiocarcinoma (perihilar CC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC), defined according to the anatomical location. These adenocarcinomas mostly comprise biliary epithelial cell-derived malignant cells. In addition to anatomical differences, there are morphological and biological differences in BTC starting from embryonic development of the tissues extending to physiological differences. Fatty acid-binding proteins (FABPs) are closely associated with the energy metabolism. Using surgical specimens from 74 BTCs, we performed immunohistochemistry for FABP5 and its associated molecules, including peroxisome proliferator-activated receptor γ (PPARγ), PPARγ coactivator 1 (PGC-1), and estrogen-related receptor α (ERRα). We found that the expression patterns of small BTCs (ICC and CoCC) considerably differed from those of large BTCs (perihilar CC, ECC, and GBC). Expression of FABP5 and PGC-1 in large BTCs was high compared with those of small BTCs, but no difference in the expression of PPARγ and ERRα was observed. FABP5 appears to play a role in malignant progression in large BTCs. Small and large BTCs possess different energy metabolism systems owing to their different anatomical locations and course of carcinogenesis, although all BTCs originate from biliary epithelial cells.

Identifiants

pubmed: 31432248
doi: 10.1007/s00795-019-00230-9
pii: 10.1007/s00795-019-00230-9
doi:

Substances chimiques

FABP5 protein, human 0
Fatty Acid-Binding Proteins 0
PPAR gamma 0
PPARG protein, human 0
PPARGC1A protein, human 0
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha 0
Receptors, Estrogen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-49

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology of Japan
ID : 17H04058

Références

Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Int J Cancer. 2006 Jun 15;118(12):3089-94
pubmed: 16395699
J Mol Cell Cardiol. 2011 Oct;51(4):578-83
pubmed: 20888832
Hum Pathol. 2012 Dec;43(12):2149-56
pubmed: 22647350
Trends Endocrinol Metab. 2002 Jul;13(5):220-5
pubmed: 12185669
Endocr Rev. 2008 Oct;29(6):677-96
pubmed: 18664618
J Nutr. 2007 Apr;137(4):992-8
pubmed: 17374666
Oncotarget. 2018 Aug 3;9(60):31753-31770
pubmed: 30167092
J Am Coll Cardiol. 2006 Aug 15;48(4):677-85
pubmed: 16904534
J Hepatobiliary Pancreat Sci. 2018 Mar;25(3):181-187
pubmed: 29272078
Cardiol Res Pract. 2012;2012:178675
pubmed: 21961074
Oncogene. 2003 May 8;22(18):2739-49
pubmed: 12743598
Nat Rev Cancer. 2004 Sep;4(9):695-706
pubmed: 15343276
Gastroenterol Jpn. 1989 Jun;24(3):308-14
pubmed: 2501138
Curr Opin Lipidol. 2001 Jun;12(3):267-74
pubmed: 11353329
Int J Oncol. 2014 Jan;44(1):265-75
pubmed: 24189640
Nutr Rev. 2013 Aug;71(8):511-27
pubmed: 23865797
J Invest Dermatol. 1992 Sep;99(3):299-305
pubmed: 1512466
Prev Med. 2014 Aug;65:13-22
pubmed: 24721739
Nutr Clin Pract. 2010 Dec;25(6):634-40
pubmed: 21139128
Int J Epidemiol. 1993 Apr;22(2):207-14
pubmed: 8505175
Cell Mol Life Sci. 2002 Jul;59(7):1096-116
pubmed: 12222958
Cancer Med. 2017 May;6(5):1049-1061
pubmed: 28374947
Proc Nutr Soc. 2008 Aug;67(3):253-6
pubmed: 18452640
J Hepatobiliary Pancreat Surg. 2001;8(4):295-302
pubmed: 11521174
Nat Rev Gastroenterol Hepatol. 2012 Feb 28;9(4):231-40
pubmed: 22371217
J Am Coll Cardiol. 2004 Jul 7;44(1):152-8
pubmed: 15234425
Histol Histopathol. 2014 Jan;29(1):1-10
pubmed: 24108502
Am J Clin Nutr. 2004 Oct;80(4):1029-35
pubmed: 15447916
Prog Lipid Res. 2004 Jul;43(4):328-49
pubmed: 15234551
BMC Dev Biol. 2011 Sep 26;11:56
pubmed: 21943389
Oncotarget. 2016 Feb 23;7(8):9322-39
pubmed: 26814431
Biochem J. 2001 Nov 15;360(Pt 1):159-65
pubmed: 11696003
Electrophoresis. 1999 Oct;20(14):2952-60
pubmed: 10546833
Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):167-77
pubmed: 17696726
J Gastrointest Oncol. 2017 Jun;8(3):430-440
pubmed: 28736630
Mol Cell Biol. 2009 Aug;29(15):4091-102
pubmed: 19451226
Am J Clin Nutr. 2006 Jun;83(6):1369-79
pubmed: 16762949
Virchows Arch. 2012 Mar;460(3):281-9
pubmed: 22358181
J Clin Pathol. 2013 May;66(5):386-91
pubmed: 23423517
N Engl J Med. 1999 Oct 28;341(18):1368-78
pubmed: 10536130
Med Mol Morphol. 2016 Dec;49(4):189-202
pubmed: 27350291

Auteurs

Risa Nakagawa (R)

Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8640, Japan.

Nguyen Canh Hiep (NC)

Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8640, Japan.

Hirofumi Ouchi (H)

Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8640, Japan.

Yasunori Sato (Y)

Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8640, Japan.

Kenichi Harada (K)

Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8640, Japan. kenichih@med.kanazawa-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH